AC
CBIO

Athanor Capital’s Crescent Biopharma CBIO Stock Holding History

Athanor Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-479
Closed -$147K – 741
2020
Q3 		$147K Sell
479
-235
-33% -$89.8K 0.01% 511
2020
Q2 		$268K Buy
714
+400
+127% +$113K 0.01% 431
2020
Q1 		$72K Sell
314
-282
-47% -$108K ﹤0.01% 160
2019
Q4 		$315K Buy
+596
New +$323K 0.01% 303

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Athanor Capital's CBIO Position: Q4 2020 in Review

Athanor Capital sold out of Crescent Biopharma (CBIO) in Q4 2020, closing a stake of 479 shares — an estimated $147K sold.

Athanor Capital first reported a position in CBIO in Q4 2019 and held it in 4 quarters. The position peaked at $315K in Q4 2019. 89 funds tracked by Wall St. Rank hold CBIO as of Q4 2020.

  • Athanor Capital reported no remaining Crescent Biopharma position as of Q4 2020 after selling out during the quarter.
  • Athanor Capital sold 479 Crescent Biopharma shares in Q4 2020, an estimated $147K.
  • Athanor Capital first reported a position in Crescent Biopharma in Q4 2019 and held it in 4 quarters.
  • Athanor Capital's Crescent Biopharma position peaked at $315K in Q4 2019.
  • 89 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2020.

Based on Athanor Capital's 13F filing for Q4 2020, filed 16 Feb 2021.